Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections

Figure 2

Flow cytometry at diagnosis showed 33% of blasts distributed in 3 populations. 1^st population, myeloid without differentiation (15%), in red: CD34++, CD117 +, HLA-DR +, CD45 + d, CD13+, CD64 −, CD35−/+ d, CD36−, CD33 +, CD71−/ +, CD105 + d, CD7−/ +, CD15−/ +, CD22−, CD38 +, CD123 +, CD4+d, and cMPO−. 2^nd population, dendritic (13%), in blue: CD34+d, CD117−/+, HLA-DR++, CD45+d, CD13 +, CD64−/ +, CD35−, CD36−/ +, CD33++, CD71−/+, CD105 + d, CD7−/+, CD15−/+, CD22−, CD38 +, CD123++, CD4 + d, and cMPO−/ +. 3^rd population, myeloid (5%), in yellow: CD34 + d, CD117 + d, HLA-DR−/+, CD45 + d, CD13 +, CD64−, CD35−, CD36−, CD33−, CD71−, CD105−, CD7−, CD15−, CD22 +, CD38−, CD123−, CD4−/+d, and cMPO−. Blasts were negative for CD10, CD16, CD11b, CD14, IREM-2, nTdT, CD56, CD19, 7.1, CD42, CD61, CD203c, cCD79a, cCD3, and CD3.